Ozanimod (Zeposia) for Multiple Sclerosis

Date: August 24, 2020
Issue #: 
1605Summary: 
The FDA has approved ozanimod (Zeposia– Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third o ral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod(Mayzent) is also indicated for use
in adults, and fingolimod(Gilenya) is approved for use
in patients≥10 years old.

Source: The Medical Letter - July 21, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Arzerra Aubagio Avonex Copaxone dimethyl fumarate diroximel Fingolimod Gilenya Glatect Glatiramer acetate Glatopa Interferon beta Lemtrada Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Ofatumu Source Type: research